Navigation Links
Confirmation of Strong Growth Over the First Half of 2008
Date:8/1/2008

Record Revenue of EUR1.55 Million (+45.5% at Constant Forex)

Substantial Increase in Sales of the JAK2 Test: +169%

LUMINY, France, August 1 /PRNewswire-FirstCall/ -- IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces its revenue for its first half to 30 June 2008.

(in thousands of 30 June 2007 30 June 2008 Variation Variation

euros)* at constant

forex

Revenue from products 879 1,415 +,61.2%

Revenue from services 218 137 -37.2%

Consolidated total 1,096 1,552 +41.6% + 45.6%

*non audited data, IFRS For the first half of 2008, revenue totaled EUR1.55 million versus EUR1.09 million for the same period of 2007, an increase of 45.5% at constant forex. At real currency rates, revenue growth was 41.6%.

Sales were up for IPSOGEN's entire portfolio of leukemia tests, but the JAK2 test recorded the most spectacular growth (+169%) despite the fact that this test only obtained CE certification towards the end of the period.

Vincent Fert, President and CEO, states: "We are very pleased with our achievements over this first half. The growth in activity was buoyant and in line with our expectations. These results confirm the potential of the JAK2 test in the diagnosis of myeloproliferative disorders and show that IPSOGEN's product portfolio is perfectly positioned to benefit from the molecular diagnosis of cancer market's very dynamic growth."

About IPSOGEN

IPSOGEN develops and markets molecular diagnostic assays for patients with cancer. With more than 60 products already used routinely in more than 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now also targeting breast cancer with the aim of providing diagnostic information that has been inaccessible until now. IPSOGEN intends to establish itself as a world leader in the molecular diagnosis of cancer. The company is pursuing the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society in general. IPSOGEN has a workforce of some 40 people in France and the United States.

Publication of results for the first half of 2008: 9 October 2008 (after market)


'/>"/>
SOURCE IPSOGEN
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
4. U-M research: New plastic is strong as steel, transparent
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Cephalon Announces Strong Third Quarter Financial Results
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Genoptix Reports Strong Financial Results For Third Quarter 2007
11. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):